Zhejiang Cancer Hospital
🇨🇳China
a Single Arm, Phase II Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of Iparomlimab and Tuvonralima b and Chemotherapy ± Bevacizumab Induction Therapy Followed by Concurrent Chemoradiotherapy in Patients With Advanced Cervical Cancer .
Phase 2
Not yet recruiting
- Conditions
- Cervical Cancer Stage IVACervical Cancer Metastatic
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 46
- Registration Number
- NCT07035808
Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer
Phase 2
Recruiting
- Conditions
- Breast Cancer
- Interventions
- Drug: pyrotinib dalpiciclib letrozole
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 63
- Registration Number
- NCT07014410
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Effect of Trendelenburg Positioning on Anesthesia-Induced Hypotension in Elderly Patients
Not Applicable
Recruiting
- Conditions
- Hypotension on InductionOld Age
- First Posted Date
- 2025-05-13
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 168
- Registration Number
- NCT06968091
- Locations
- 🇨🇳
Zhejiang cancer hospital, Hangzhou, Zhejiang, China
Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma
Phase 2
Not yet recruiting
- Conditions
- BTK InhibitorsFollicular LymphomaImmunochemotherapy
- Interventions
- Drug: ZGCVP
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 58
- Registration Number
- NCT06918015
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
SH-LPS System in Preoperative Planning for Liver Resection
Phase 2
Not yet recruiting
- Conditions
- Liver Tumor; Surgery3D PrintingPreoperative Planning
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06911086
Real World Study of Bone Metastases in Patients with Advanced Breast Cancer
Completed
- Conditions
- Breast Cancer Metastatic
- First Posted Date
- 2025-03-13
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 737
- Registration Number
- NCT06873997
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Zhejiang, China
Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal Metastases
Phase 2
Not yet recruiting
- Conditions
- Leptomeningeal Metastases
- Interventions
- Drug: vometinib
- First Posted Date
- 2025-03-06
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT06861218
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
The Formulation of Compound Phellinus Igniarius Decoction on Radiation Pneumonitis
Phase 1
Completed
- Conditions
- Radiation Pneumonitis
- Interventions
- Drug: The formulation of Compound Phellinus igniarius decoction
- First Posted Date
- 2025-03-06
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06861179
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, HangZhou, Zhejiang, China
Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL
Not Applicable
Recruiting
- Conditions
- Primary Central Nervous System Lymphoma
- Interventions
- Drug: Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT)
- First Posted Date
- 2025-02-18
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 44
- Registration Number
- NCT06832267
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody （PPR） in Third or Later Line Therapy of DLBCL
Not Applicable
Recruiting
- Conditions
- Diffuse Large B-cell Lymphoma (DLBCL)
- Interventions
- Drug: Pomalidomide Combination With Rituximab and Anti-PD-1 Antibody （PPR）
- First Posted Date
- 2025-02-18
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06832228
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China